Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Roche Holding Ltd. : UPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Roche Holding AG and Reminds Investors with Losses to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
07/17/2017 | 10:03pm CEST

IRVINE, CA / ACCESSWIRE / July 17, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Roche Holding AG ("Roche Holding" or the "Company") (OTCQX: RHHBY). Investors, who purchased or otherwise acquired shares from March 2, 2017 through June 5, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before the August 7, 2017 lead plaintiff motion deadline.

If you purchased shares of Roche Holding during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at [email protected].

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

According to the Complaint, throughout the Class Period, Roche Holding issued materially false and misleading statements and/or failed to disclose material information, specifically that the combination of the Company's breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer, and has a higher rate of side effects. Following this news, Roche Holding's stock price dropped materially, causing investors harm according to the Complaint.

If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions.


Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]

SOURCE: Khang & Khang LLP

© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
06/15Roche's Gazyva Cancer Drug Outperforms MabThera
06/14Roche to Present Ocrevus Data Showing Delayed Wheelchair Need in MS Patients
06/14GENENTECH : Announces New OCREVUS (Ocrelizumab) Data on Long-Term Disability Ben..
06/13ROCHE : CORRECTING and REPLACING FDA Approves Genentech’s Avastin (Bevaciz..
06/13Sanofi says on track to regain solid position in cancer drugs
06/11Takeda shareholder group aims to block $62 billion Shire deal
06/11Takeda shareholder group aims to block $62 billion Shire deal
06/11Roche's Venclexta Plus Rituxan Gets FDA Approval as Leukemia Treatment
06/08GENENTECH : Announces FDA Approval for Venclexta Plus Rituxan for People with Pr..
06/07ROCHE : FDA Approves Genentech’s Rituxan (rituximab) For Pemphigus Vulgari..
More news
News from SeekingAlpha
06/153 Big Pharma Companies May Get A Big Boost From Trump 
06/15YOUR DAILY PHARMA SCOOP : Wright Receives PMA, Allergan And Corbus Report Positi.. 
06/14Autolus Therapeutics Readies $125 Million U.S. IPO 
06/13FDA OKs expanded use for Roche's Avastin 
06/12Roche Pulls Out An FDA Win For Venclexta, A Much Needed Win For Pipeline Expa.. 
Financials ( CHF)
Sales 2018 55 696 M
EBIT 2018 18 523 M
Net income 2018 12 023 M
Debt 2018 4 036 M
Yield 2018 4,13%
P/E ratio 2018 14,57
P/E ratio 2019 14,01
EV / Sales 2018 3,35x
EV / Sales 2019 3,17x
Capitalization 183 B
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 256  CHF
Spread / Average Target 22%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-14.06%183 969
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 446
MERCK AND COMPANY10.24%166 880
AMGEN6.39%122 422